Skip to content

Innovative Robotic Gait Trainer Use to Enable Walking in Children With Cerebral Palsy GMFCS III and IV

Innovative Robotic Gait Trainer Use to Enable Walking in Children With Cerebral Palsy GMFCS III and IV

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05378243
Enrollment
10
Registered
2022-05-18
Start date
2021-11-08
Completion date
2024-07-31
Last updated
2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Brief summary

Exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (RGT) group, and functional clinical therapy (FCT) using each subject as their own control.

Detailed description

Exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (RGT) group, and functional clinical therapy (FCT) using each subject as their own control. The primary objective is to assess feasibility of the study design and device tolerability. Specifically: * Recruitment success (number screened, number eligible, number enrolled) where 80% of the recruitment target is reached. * Attrition rates of less than 10% (i.e. ≥90% of participant's successfully complete assessments). * Adherence for each participant: 80% of participants who complete assessments achieve the minimum target dose (i.e. approx. ≥30 hours of therapy in both study groups). * Qualitative feedback from clinicians and patients/caregivers on device tolerability and study participation. Secondary objectives will evaluate the distance a child can walk in two minutes using the Two Minute Walk Test (2MWT, 18) and will examine a more global impact of the use of this technology. Data collected will include quality of gait, child or proxy chosen individualized goals, hypertonicity, contractures, and bone health.

Interventions

Use of a walker adapted with robotic components to promote proper walking gait

BEHAVIORALFunctional Clinical Therapy

Personalized program of physical therapy targeted to improving walking gait

Sponsors

Ontario Brain Institute
CollaboratorOTHER
Academic Health Science Centres
CollaboratorOTHER
Children's Hospital of Eastern Ontario
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

Randomized crossover trial

Eligibility

Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Patients with a diagnosis of cerebral palsy * GMFCS Levels III and IV * Ages ≥2 to ≤12 years * Ability to take steps with and/or without assistance * Meet the Trexo Plus device size requirements * Ability to follow instructions and signal pain, fear, or discomfort * Ability to safely use the device at home as determined by the study team

Exclusion criteria

* Lower limb or orthopedic surgery within 9 months prior to enrollment * Botulinum toxin injections within 4 months prior to enrollment * Serial casting within 3 months prior to enrollment * Knee flexion contracture \> 20° * Knee valgus \> 40° * Hip subluxation \> 40 % migration percentage * Uncontrolled movements that prevent transfer in and/or out of device * Weight bearing restrictions * Uncontrolled seizures * Skin lesions in areas where the device straps would be attached * Significant language barrier with parents and/or caregivers Note: children with severe contractures will be unable to fit in the device and are therefore excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
Enrollment and recruitment in this study design4 monthsRecruitment success as defined by meeting 80% of the recruitment target
Retention in this study design4 monthsAttrition of less than 10% where 90% of participants are completing the assessments to the end of the trial
Adherance to protocol for each participant4 monthsParticipant self-reported session diaries will be assessed to determine whether participants are achieving the min target dose of 30h of therapy over each 8 week session
Device tolerability4 monthsParticipant caregivers will be interviewed for qualitative feedback on device/therapy tolerability after each 8 week session

Secondary

MeasureTime frameDescription
Hypertonia Assessment Tool4 monthsAssessing dystonia, spasticity, and rigidity, or a mixed tone through a rating scale system where 0 indicates the behavior is not observed and 1 indicates the dystonic/spastic/rigid behavior is observed.
Barry Albright Dystonia Scale4 monthsAssessing dystonia and severity of dystonia in eyes, mouth, neck, trunk, each upper extremity and each lower extremity. Scored from 0-4 where 0 is an absence of dystonia and 4 is a high degree of dystonia.
Goal attainment scale4 monthsAttainment of self-determined goals for treatment outcomes. Goals are set with the study therapists at the outset of each treatment period and assessed using a scale of -2 to +2 where a score of 0 is the expected outcome, a negative score indicates less than expected and a positive number indicates more than expected
2 minute walk test (2mwt)4 monthsdistance child is able to walk in their own walker in 2 minutes
Leg Bone cortical density4 monthsperipheral Quantitative Computed Tomography (pQCT) Measures Cortical density (mg/cm2)
Tibia volumetric bone mineral density (BMD)4 monthsperipheral Quantitative Computed Tomography (pQCT) Measures Tibia volumetric bone mineral density (BMD) (mg/cm2)
Leg bone cortical cross-sectional area4 monthsperipheral Quantitative Computed Tomography (pQCT) Measures cortical cross-sectional area (mm2)
Spinal Alignment and Range of Motion Measure4 monthsRange of motion throughout the body is measured from 0-4 where 0 is no limitation and 4 is a severe limitation.
Edinburgh Visual Gait Score4 monthsEdinburgh Visual Gait Score is used for assessing gait quality by assessing body positions and angles of various body parts through the gait pattern using a scale of 0-2 for each individual component of the assessment. A score of 0 indicates a more physiologically normal result while a score of 2 indicates a more disordered result. The scores are totaled to provide the complete score for the patient on this assessment
Physiological Cost Index4 monthsassessing gait efficiency by looking at the heart rate changes upon a specified exertional task. A lower physiological cost index indicates less exertion required to complete the task
Modified Ashworth Scale4 monthsThe Modified Ashworth Scale measures resistance during passive soft tissue stretching. It is ranked by body part on a scale of 0-4 with 0 being a normal tone and 4 being highly rigid in flexion or extension.

Countries

Canada

Contacts

Primary ContactMichelle Larin
MLarin@cheo.on.ca6137377600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026